#Free clinical trials for prostate cancer in charlotte nc series
There is a large number of these clinically indolent tumors, estimated from autopsy series of men dying of causes unrelated to prostate cancer to range from 30% to 70% of men older than 60 years.īecause diagnostic methods have changed over time, any analysis of survival after treatment of prostate cancer and comparison of the various treatment strategies is complicated by the evidence of increasing diagnosis of nonlethal tumors. In part, these favorable outcomes are likely the result of widespread screening with the prostate-specific antigen (PSA) test, which can identify patients with asymptomatic tumors that have little or no lethal potential. Many patients-especially those with localized tumors-may die of other illnesses without ever having suffered disability from the cancer, even if managed conservatively without an attempt at curative therapy.
Side effects of various forms of treatment should be considered in selecting appropriate management. The approach to treatment is influenced by age and coexisting medical problems. The 5-year relative survival rate for men diagnosed in the United States from 2011 to 2017 with local or regional disease was greater than 99%, and the rate for distant disease was 31% a 98% survival rate was observed for all stages combined. The rate of tumor growth varies from very slow to moderately rapid, and some patients may have prolonged survival even after the cancer has metastasized to distant sites, such as bone. Prostate cancer may be cured when localized, and it frequently responds to treatment when widespread. The median age at diagnosis of carcinoma of the prostate is 67 years.
0 kommentar(er)
